Clinical trials: Adaptive Radiotherapy
Pancreatic Cancer, Stereotactic Body Radiation Therapy
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
The purpose of the phase I/II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with Avasopasem manganese (GC4419) or placebo to patients who have been diagnosed with…
- Trial name
- NCT03340974
- Testing
- GC4419, Stereotactic Radiation Therapy (SBRT) 50 Gy, Stereotactic Radiation Therapy (SBRT) 55 Gy
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Galera Therapeutics, Inc.
Prostate Cancer (Adenocarcinoma), Prostate CA
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer.
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy)
- Trial name
- NCT06636682
- Testing
- FK-PC101, Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cellvax Therapeutics Inc
Stage III Non-small Cell Lung Cancer
Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer
This is a prospective multi-center randomized clinical trial designed to demonstrate that daily online adaptive radiotherapy with concomitant chemotherapy for stage III non-small cell lung cancer (NSCLC) will result in decreased…
- Trial name
- ARTIA-Lung (NCT05488626)
- Testing
- Adaptive Radiotherapy, Non-Adaptive Radiotherapy, Chemotherapy
- Where
- United States
- Sponsor
- Varian, a Siemens Healthineers Company
Acute Leukemia, Myeloid Leukemia
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
This is a multicenter, open-label study in people aged 18 and older with relapsed or refractory acute myeloid leukemia. It has two parts.
- Conditions
- Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07157514
- Testing
- 131I-apamistamab, Fludarabine, Cyclophosphamide
- Volunteers
- 306 people
- Sponsor
- Actinium Pharmaceuticals
Pancreatic Cancer
Locally Advanced Pancreatic Cancer Treated With ABLAtivE Stereotactic MRI-guided Adaptive Radiation Therapy
Ablative dose magnetic resonance imaging (MRI) guided hypofractionated radiation therapy delivered using daily adaptive dose planning has shown to improve overall survival, relative to patients receiving lower radiation doses, in…
- Trial name
- LAP-ABLATE (NCT05585554)
- Testing
- MRIdian
- Volunteers
- 267 people
- Sponsor
- Viewray Inc.
Pancreatic Cancer
Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer
High-dose magnetic resonance imaging (MRI) guided hypofractionated radiation therapy delivered using daily adaptive dose planning has been shown in a retrospective study to result in improved overall survival, relative to…
- Trial name
- NCT03621644
- Testing
- Stereotactic MRI-guided On-table Adaptive Radiation Therapy
- Where
- 13 sites in United States, Israel
- Volunteers
- 133 people
- Sponsor
- Viewray Inc.
Muscle Invasive Bladder Urothelial Carcinoma
Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle-invasive bladder cancer will translate into a decreased rate of acute (assessed weekly during…
- Trial name
- ARTIA-Bladder (NCT05700227)
- Testing
- Daily Adaptive External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Varian, a Siemens Healthineers Company
Pancreatic Cancer
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced …
- Trial name
- ARTIA-Pancreas (NCT05764720)
- Testing
- Daily Adaptive External Beam Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 134 people
- Sponsor
- Varian, a Siemens Healthineers Company
Prostate Cancer
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased…
- Trial name
- ARTIA-Prostate (NCT05804318)
- Testing
- Daily adaptive SBRT with urethral sparing
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 132 people
- Sponsor
- Varian, a Siemens Healthineers Company
Chronic Radiation Ulcer
Study to Evaluate the Safety, Tolerability, and Efficacy of PEP-TISSEEL in Subjects With Chronic Radiation Ulcer
The goal of this clinical trial is to learn if drug Purified Exosome Product (PEP™) and Fibrin Sealant (TISSEEL® VH SD Kit) (PEP-TISSEEL) works to treat chronic radiation ulcer in adults and compare it with comparator TISSEEL.
- Trial name
- NCT06793748
- Testing
- PEP-TISSEEL, TISSEEL Fibrin Sealant KIT
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Rion Inc.
Muscle-Invasive Bladder Carcinoma
Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach
This is a single-arm, prospective, Phase II, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle invasive bladder cancer will translate into a decreased rate of acute gastrointestinal…
- Trial name
- ARTIA-Vesica (NCT05295992)
- Testing
- Varian Ethos Adaptive Radiation Therapy
- Where
- Denmark
- Volunteers
- 110 people
- Sponsor
- Varian, a Siemens Healthineers Company
Cervical Cancer by FIGO Stage 2018
Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity…
- Trial name
- ARTIA-Cervix (NCT05197881)
- Testing
- Varian Ethos Adaptive Radiation Therapy
- Where
- 5 sites in United States
- Volunteers
- 125 people
- Sponsor
- Varian, a Siemens Healthineers Company